These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 2110281)

  • 1. Bone marrow transplantation in lysosomal storage diseases: a prelude to gene-insertion therapy.
    Yeager AM
    Md Med J; 1990 Apr; 39(4):337-41. PubMed ID: 2110281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone marrow transplantation for Pompé's disease.
    Hoogerbrugge PM; Wagemaker G; van Bekkum DW; Reuser AJ; vd Ploeg AT
    N Engl J Med; 1986 Jul; 315(1):65-6. PubMed ID: 3086726
    [No Abstract]   [Full Text] [Related]  

  • 3. Bone marrow transplantation and gene therapy for lysosomal storage diseases.
    Hoogerbrugge PM; Valerio D
    Bone Marrow Transplant; 1998 Apr; 21 Suppl 2():S34-6. PubMed ID: 9630322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Lysosomal glycogen storage disease without acid maltase deficiency (Danon's disease)].
    Usuki F
    Ryoikibetsu Shokogun Shirizu; 1998; (19 Pt 2):353-5. PubMed ID: 9645081
    [No Abstract]   [Full Text] [Related]  

  • 5. More on bone marrow transplantation for glycogen storage disease type II (Pompé's disease).
    Hug G
    N Engl J Med; 1986 Nov; 315(19):1229. PubMed ID: 3531866
    [No Abstract]   [Full Text] [Related]  

  • 6. Perspectives on gene therapy for lysosomal storage diseases that affect hematopoiesis.
    Grabowski GA
    Curr Hematol Rep; 2003 Jul; 2(4):356-62. PubMed ID: 12901334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysosomal glycogen storage disease without deficiency of acid alpha-glucosidase.
    Ullrich K; von Bassewitz D; Shin J; Korinthenberg R; Sewell S; von Figura K
    Prog Clin Biol Res; 1989; 306():163-71. PubMed ID: 2500669
    [No Abstract]   [Full Text] [Related]  

  • 8. [Lysosomal glycogen storage disease without acid maltase deficiency(Danon disease)].
    Ohno K
    Ryoikibetsu Shokogun Shirizu; 2000; (29 Pt 4):491-2. PubMed ID: 11032005
    [No Abstract]   [Full Text] [Related]  

  • 9. Bone marrow transplantation in type IIa glycogen storage disease.
    Harris RE; Hannon D; Vogler C; Hug G
    Birth Defects Orig Artic Ser; 1986; 22(1):119-32. PubMed ID: 3516240
    [No Abstract]   [Full Text] [Related]  

  • 10. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.
    Raben N; Fukuda T; Gilbert AL; de Jong D; Thurberg BL; Mattaliano RJ; Meikle P; Hopwood JJ; Nagashima K; Nagaraju K; Plotz PH
    Mol Ther; 2005 Jan; 11(1):48-56. PubMed ID: 15585405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete correction of acid alpha-glucosidase deficiency in Pompe disease fibroblasts in vitro, and lysosomally targeted expression in neonatal rat cardiac and skeletal muscle.
    Pauly DF; Johns DC; Matelis LA; Lawrence JH; Byrne BJ; Kessler PD
    Gene Ther; 1998 Apr; 5(4):473-80. PubMed ID: 9614571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Allogeneic bone marrow transplantation in the treatment of (lysosomal) storage diseases].
    Maaswinkel-Mooij PD; Poorthuis BJ; Hoogerbrugge PM; Brouwer OF; Vossen JM
    Ned Tijdschr Geneeskd; 1998 Jan; 142(4):169-74. PubMed ID: 9557021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prenatal diagnosis in glycogen storage diseases.
    Chen YT; Bali D; Sullivan J
    Prenat Diagn; 2002 May; 22(5):357-9. PubMed ID: 12001186
    [No Abstract]   [Full Text] [Related]  

  • 14. Current and emerging therapies for the lysosomal storage disorders.
    Pastores GM; Barnett NL
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):891-902. PubMed ID: 16262569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycogen storage in multiple muscles of old GSD-II mice can be rapidly cleared after a single intravenous injection with a modified adenoviral vector expressing hGAA.
    Xu F; Ding E; Migone F; Serra D; Schneider A; Chen YT; Amalfitano A
    J Gene Med; 2005 Feb; 7(2):171-8. PubMed ID: 15515143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene therapy for the lysosomal storage disorders.
    Cabrera-Salazar MA; Novelli E; Barranger JA
    Curr Opin Mol Ther; 2002 Aug; 4(4):349-58. PubMed ID: 12222873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycogen storage disease type II (Pompe's disease): the first biochemical evidence in Thailand.
    Rangdaeng S; Scollard DM; Srichairatanakol S; Sutthachit M; Phornphutkul C
    J Med Assoc Thai; 1987 Sep; 70(9):536-42. PubMed ID: 2960768
    [No Abstract]   [Full Text] [Related]  

  • 18. The presence of an autologous marrow stromal cell layer increases glucocerebrosidase gene transduction of long-term culture initiating cells (LTCICs) from the bone marrow of a patient with Gaucher disease.
    Wells S; Malik P; Pensiero M; Kohn DB; Nolta JA
    Gene Ther; 1995 Oct; 2(8):512-20. PubMed ID: 8593601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies.
    Uderzo C; Dini G; Locatelli F; Miniero R; Tamaro P
    Haematologica; 2000 Nov; 85(11 Suppl):47-53. PubMed ID: 11268324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stop-codon read-through for patients affected by a lysosomal storage disorder.
    Brooks DA; Muller VJ; Hopwood JJ
    Trends Mol Med; 2006 Aug; 12(8):367-73. PubMed ID: 16798086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.